What comes first: digital health innovation or regulatory policy? Disruptive innovations are abounding in clinical research with virtual remote clinical trials, big data and the call for standardization of data in translational and clinical research.
Join a panel of clinical research leaders and regulatory experts as they discuss how the combination of health technology and policy have advanced health outcomes over the past six months. The discussion will explore how to create the right balance to encourage innovation in clinical research, while still offering the necessary guardrails for the industry to confidently establish rapid priorities and adopt emerging innovation.
- Craig Lipset, Founder, Clinical Innovation Partners
- Munther Baara, Vice President, Product Strategy and Innovation, EDETEK
- Susan Dentzer, Visiting Fellow, Duke-Margolis Center For Health Policy
- John Hariadi, Associate Director for Knowledge Management, Data Analytics and Technology Assistance, Office of Translational Sciences, Center for Drug Evaluations and Research, U.S. Food and Drug Administration
- Robert Goodwin, Vice President, Head of Operations, Center of Excellence, Pfizer, ILT TransCelerate Biopharma Inc.
This session is part of a three-part series, The Digital Core Competencies: Clinical Research Informatics for the Pharma Industry, exploring the intersection of the pharma workforce with clinical informatics and research. Each webinar features a panel discussion with an opportunity for audience questions. Attendees will be awarded a certificate of completion from Duke University School of Medicine MMCi.
The views and opinions expressed in this content or by commenters are those of the author and do not necessarily reflect the official policy or position of HIMSS or its affiliates.